Emerging utility of once-weekly exenatide in patients with type 2 diabetes
Aditya Goud, Jixin Zhong, Sanjay RajagopalanDivision of Cardiovascular Medicine, Department of Medicine, University of Maryland, Baltimore, MD, USAAbstract: Type 2 diabetes mellitus (T2DM) is a major risk factor for the development of cardiovascular disease (CVD). Due to the ever increasing incidenc...
Guardado en:
Autores principales: | Goud A, Zhong J, Rajagopalan S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/90df0cef555e4836a09f0443ce732411 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
por: Mann KV, et al.
Publicado: (2014) -
Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Jason Seewoodhary, et al.
Publicado: (2010) -
Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
por: MacConell L, et al.
Publicado: (2015) -
Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders WB, et al.
Publicado: (2016) -
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
por: MacConell L, et al.
Publicado: (2013)